Prophylactic antibiotics cut risk of anti-EGFR skin rash

Prophylactic antibiotics cut risk of anti-EGFR skin rash

(HealthDay)—For patients receiving anti-epidermal growth factor receptor (EGFR) treatment, the risk of developing skin rash is reduced for those taking prophylactic antibiotics, according to a review published online May 23 in the British Journal of Dermatology.

Fausto Petrelli, M.D., from Piazzale Ospedale in Treviglio, Italy, and colleagues conducted a systematic review and meta-analysis to examine whether can reduce the occurrence and severity of anti-EGFR drug-related skin rashes. Data were included for 1,073 from 13 studies.

The researchers found that, compared to patients without , patients in the prophylactic antibiotic arms had a reduced risk of developing a skin rash in all studies (odds ratio, 0.53). Based on 12 studies, moderate-to-severe toxicities were reduced by almost 70 percent (odds ratio, 0.32). This corresponded to a 26 percent absolute difference of high-grade skin rash versus control arms (from 50 to 24 percent).

"Taking preemptive tetracyclines for several weeks at the start of anti-EGFR treatment can significantly reduce the incidence and severity of cutaneous acneiform rash," the authors write.

Explore further

Toxic skin effects common with EGFR-TKI use in NSCLC

More information: Abstract
Full Text (subscription or payment may be required)
Journal information: British Journal of Dermatology

Copyright © 2016 HealthDay. All rights reserved.

Citation: Prophylactic antibiotics cut risk of anti-EGFR skin rash (2016, June 1) retrieved 29 May 2022 from
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.

Feedback to editors